Found: 36
Select item for more details and to access through your institution.
Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 627, doi. 10.1007/s10637-017-0444-1
- By:
- Publication type:
- Article
BRINGING SOUTHERN BLUEFIN TUNA BACK FROM THE BRINK: ENHANCING UNDERSTANDING OF THE SCIENTIFIC PROCESS IN THE WESTERN AND CENTRAL PACIFIC FISHERIES COMMISSION.
- Published in:
- Boston College Environmental Affairs Law Review, 2015, v. 42, n. 2, p. 347
- By:
- Publication type:
- Article
A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Third-Generation Aromatase Inhibitors: Differences between the Agents and Their Role in Reducing the Risk of Distant Metastasis and Improving Survival.
- Published in:
- European Journal of Clinical & Medical Oncology, 2010, v. 2, n. 4, p. 1
- By:
- Publication type:
- Article
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231187201
- By:
- Publication type:
- Article
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221113694
- By:
- Publication type:
- Article
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 195, n. 1, p. 55, doi. 10.1007/s10549-022-06662-9
- By:
- Publication type:
- Article
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 195, n. 2, p. 127, doi. 10.1007/s10549-022-06602-7
- By:
- Publication type:
- Article
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 167, n. 3, p. 671, doi. 10.1007/s10549-017-4537-5
- By:
- Publication type:
- Article
Safety of Bevacizumab in Patients with Metastatic Breast Cancer.
- Published in:
- Oncology, 2011, v. 80, n. 5/6, p. 314, doi. 10.1159/000328757
- By:
- Publication type:
- Article
A Breakthrough in the Treatment of Metastatic Triple-Negative Breast Cancer.
- Published in:
- Conquer, 2019, v. 5, n. 5, p. 38
- By:
- Publication type:
- Article
Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: A phase II randomized trial.
- Published in:
- Acta Oncologica, 2014, v. 53, n. 1, p. 65, doi. 10.3109/0284186X.2013.781673
- By:
- Publication type:
- Article
Phase 1b study of pan‐AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN‐mutated advanced solid tumors.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 12, p. 1919, doi. 10.1002/cncr.34733
- By:
- Publication type:
- Article
Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion.
- Published in:
- 2013
- By:
- Publication type:
- Correction notice
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].
- Published in:
- 2012
- By:
- Publication type:
- journal article
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 3, p. 421, doi. 10.1007/s10637-023-01359-2
- By:
- Publication type:
- Article
Novel Endocrine Therapy Agents in ER-Positive, HER2-Negative Breast Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 3, p. 125
- By:
- Publication type:
- Article
New Approaches to Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, n. 6, p. 356
- By:
- Publication type:
- Article
Pharmacogenetic testing in the face of unclear clinical efficacy: Lessons from cytochrome P450 2D6 for tamoxifen.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Pharmacogenetic Testing in the Face of Unclear Clinical Efficacy.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 20, p. 3703, doi. 10.1002/cncr.28263
- By:
- Publication type:
- Article
A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States.
- Published in:
- BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-022-09557-6
- By:
- Publication type:
- Article
A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors.
- Published in:
- Cancers, 2022, v. 14, n. 20, p. 4996, doi. 10.3390/cancers14204996
- By:
- Publication type:
- Article
Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Advertising Willa Cather as Product.
- Published in:
- 2020, isbn. 9780803263987
- By:
- Publication type:
- Book Review
Advertising Cather during the Transition Years (1914-1922).
- Published in:
- Cather Studies, 2007, v. 7, n. 1, p. 13
- By:
- Publication type:
- Article
Novel Estrogen Receptor-Targeted Agents for Breast Cancer.
- Published in:
- Current Treatment Options in Oncology, 2023, v. 24, n. 7, p. 821, doi. 10.1007/s11864-023-01079-y
- By:
- Publication type:
- Article
How Can We Optimize Treatment of HER2-Positive Metastatic Breast Cancer?
- Published in:
- Oncology (08909091), 2013, v. 27, n. 3, p. 180
- By:
- Publication type:
- Article
Prevalence and impact of correlative science in breast cancer phase II trials.
- Published in:
- Breast Cancer Research & Treatment, 2013, v. 139, n. 3, p. 845, doi. 10.1007/s10549-013-2590-2
- By:
- Publication type:
- Article
A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR<sup>+</sup>/HER2<sup>-</sup> Breast Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Nab-Paclitaxel/Bevacizumab/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2013, v. 13, n. 6, p. 416, doi. 10.1016/j.clbc.2013.08.003
- By:
- Publication type:
- Article
First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors.
- Published in:
- International Journal of Cancer, 2019, v. 145, n. 7, p. 1798, doi. 10.1002/ijc.32154
- By:
- Publication type:
- Article
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 5, p. 569, doi. 10.1007/s11523-021-00835-0
- By:
- Publication type:
- Article